Publication:
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus

dc.date.accessioned 2018-09-14T11:15:09Z
dc.date.available 2017-07-12T03:27:52Z
dc.date.available 2014-11-18 en_US
dc.date.available 2014-11-18 en_US
dc.date.available 2014-11-18 en_US
dc.date.available 2014-11-18 en_US
dc.date.available 2014-11-18 en_US
dc.date.available 2014-11-18 en_US
dc.date.available 2014-11-18 en_US
dc.date.available 2014-11-18 en_US
dc.date.available 2014-11-18 en_US
dc.date.available 2014-11-18 en_US
dc.date.available 2014-11-18 en_US
dc.date.available 2018-09-14T11:15:09Z
dc.date.issued 2015-02-01 en_US
dc.description.abstract Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.
dc.identifier.uri https://demo7.dspace.org/handle/10673/219
dc.language English en_US
dc.title A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus en_US
dc.type Journal Article
dspace.entity.type Publication
relation.isAuthorOfPublication b1b2c768-bda1-448a-a073-fc541e8b24d9
Files
Collections